Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics.

MLA

Jering, Karola S., et al. “Prospective ARNI vs. ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.” European Journal of Heart Failure, vol. 23, no. 6, June 2021, pp. 1040–48. EBSCOhost, https://doi.org/10.1002/ejhf.2191.

APA

Jering, K. S., Claggett, B., Pfeffer, M. A., Granger, C., Køber, L., Lewis, E. F., Maggioni, A. P., Mann, D., McMurray, J. J. V., Rouleau, J.-L., Solomon, S. D., Steg, P. G., van der Meer, P., Wernsing, M., Carter, K., Guo, W., Zhou, Y., Lefkowitz, M., Gong, J., … Braunwald, E. (2021). Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction (PARADISE-MI): design and baseline characteristics. European Journal of Heart Failure, 23(6), 1040–1048. https://doi.org/10.1002/ejhf.2191

Chicago

Jering, Karola S, Brian Claggett, Marc A Pfeffer, Christopher Granger, Lars Køber, Eldrin F Lewis, Aldo P Maggioni, et al. 2021. “Prospective ARNI vs. ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events after Myocardial Infarction (PARADISE-MI): Design and Baseline Characteristics.” European Journal of Heart Failure 23 (6): 1040–48. doi:10.1002/ejhf.2191.